Target intelligence / Profile preview

Regulating synaptic membrane exocytosis protein 1 (RIMS1)

Target
RIMS1
Molecular classification
Scaffold protein, Synaptic active zone protein, Presynaptic cytomatrix protein, Rab-effector protein
01

Overview

Regulating synaptic membrane exocytosis protein 1 (RIMS1) is a multidomain scaffold protein critical for neurotransmitter release at the presynaptic active zone in neurons. As part of the cytomatrix, RIMS1 coordinates docking, priming, and exocytosis of synaptic vesicles by interacting with components including Rab3A, Munc13, voltage-gated calcium channels, and multiple active zone proteins. RIMS1 thus regulates both the probability and timing of neurotransmitter release and is essential for normal synaptic transmission and presynaptic plasticity. Mutations in RIMS1 are causative of cone-rod dystrophy 7, an inherited retinal degenerative disorder. RIMS1 also functions in nonneuronal secretory systems, such as insulin release from pancreatic β-cells and acrosomal exocytosis in sperm.

Other names
KIAA0340RAB3IP2RIM1Nbla00761RIM 1RIMRab-3-interacting molecule 1Rab-3-interacting protein 2Rab3-interacting moleculeCORD7RIMS1
02

Mechanism of action

Drugs or experimental molecules targeting RIMS1 would generally aim to modulate synaptic vesicle release, neurotransmission, or presynaptic calcium channel tethering. Mechanisms could involve inhibition or enhancement of protein-protein interactions in the active zone, or modulation of calcium channel localization.

03

Biological functions

Regulates synaptic vesicle exocytosisOrchestrates synaptic vesicle docking and neurotransmitter releaseModulates voltage-gated calcium channel activityMaintains neurotransmitter release probabilityMediates presynaptic plasticity (short-term and long-term)Involved in synaptic transmission and plasticitySupports insulin secretion (pancreatic β-cells)Essential for acrosomal exocytosis in human sperm
04

Disease associations

Neurodegenerative disease (cone-rod dystrophy type 7)Cognitive disorders (potential involvement)Other (deficits in synaptic transmission and plasticity)
05

Safety considerations

Therapeutic targeting of RIMS1 could disrupt neurotransmitter release broadly in the CNS and/or affect insulin secretion in the pancreas, posing risks of neurological and metabolic side effects.There are challenges in achieving specificity given the functional redundancy and overlap with other RIM family members
06

Interacting drugs

No clinically approved drugs specifically targeting RIMS1 are described in the current literature. Experimental studies may use molecular tools or peptides to disrupt RIMS1 interactions, but such agents are not established therapeutics.
07

Biomarkers

Genetic mutations in RIMS1 (such as those causing cone-rod dystrophy 7) may be considered biomarkers for diagnosis or patient selection in relevant inherited retinal dystrophies

Beyond the preview

Go deeper on Regulating synaptic membrane exocytosis protein 1 (RIMS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regulating synaptic membrane exocytosis protein 1 (RIMS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call